141 related articles for article (PubMed ID: 16404347)
1. Evaluation of fluorenhymustine as a rationally designed novel anticancer agent.
Samanta S; Pain A; Ghosh M; Dutta S; Sanyal U
Exp Oncol; 2005 Dec; 27(4):279-85. PubMed ID: 16404347
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Kampasi H; Qazi GN; Sanyal U
J Exp Clin Cancer Res; 2003 Sep; 22(3):411-8. PubMed ID: 14582700
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of naphthal-NU, a 2-chloroethylnitrosourea derivative of naphthalimide, as a mixed-function anticancer agent.
Samanta S; Pain A; Dutta S; Sanyal U
J Exp Clin Cancer Res; 2002 Mar; 21(1):87-93. PubMed ID: 12071535
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of substituted naphthalimide nitrogen mustards as rationally designed anticancer compounds.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Kampasi H; Quazi GN; Sanyal U
Acta Pol Pharm; 2003; 60(4):285-91. PubMed ID: 14714857
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent.
Samanta S; Pain A; Dutta S; Saxena AK; Shanmugavel M; Pandita RM; Qazi GN; Sanyal U
J Exp Ther Oncol; 2005; 5(1):15-22. PubMed ID: 16416597
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of dimethoxydop-NU as a novel anti-tumor agent.
Mukherjee A; Dutta S; Sanyal U
J Exp Clin Cancer Res; 2007 Dec; 26(4):489-97. PubMed ID: 18365543
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Sharma M; Qazi GN; Sanyal U
Acta Pol Pharm; 2007; 64(1):27-33. PubMed ID: 17665847
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of 2-chloroethylnitrosoureas of substituted naphthalimides as mixed-function anticancer compounds.
Samanta S; Pain A; Dutta S; Sanyal U
Acta Pol Pharm; 2001; 58(5):351-6. PubMed ID: 11876442
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of phthalmustine, a new anticancer compound. II. Tumor inhibitory effect in murine Ehrlich ascites carcinoma and sarcoma-180.
Bhattacharya S; Ghosh M; Sadhu U; Dutta S; Sanyal U
Neoplasma; 1996; 43(3):209-13. PubMed ID: 8841510
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.
Yamori T; Matsunaga A; Sato S; Yamazaki K; Komi A; Ishizu K; Mita I; Edatsugi H; Matsuba Y; Takezawa K; Nakanishi O; Kohno H; Nakajima Y; Komatsu H; Andoh T; Tsuruo T
Cancer Res; 1999 Aug; 59(16):4042-9. PubMed ID: 10463605
[TBL] [Abstract][Full Text] [Related]
11. Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
Su TL; Lin YW; Chou TC; Zhang X; Bacherikov VA; Chen CH; Liu LF; Tsai TJ
J Med Chem; 2006 Jun; 49(12):3710-8. PubMed ID: 16759114
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of dimethyl tin 4-cyclohexyl thiosemicarbazone as a novel antitumor agent.
Sen A; Chaudhuri TK
Exp Oncol; 2009 Mar; 31(1):22-6. PubMed ID: 19300412
[TBL] [Abstract][Full Text] [Related]
14. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
Cantrell JE; Green D; Schein PS
Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
[TBL] [Abstract][Full Text] [Related]
17. [Synthesis and antitumor activity of benzoic nitrogen mustard derivatives].
Luo W; Zhao YM; Wang YX; Xie SQ; Zhao J; Wang CJ
Yao Xue Xue Bao; 2007 Dec; 42(12):1327-9. PubMed ID: 18338650
[TBL] [Abstract][Full Text] [Related]
18. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 2-(methylaminosulfonyl)-1-(arylsulfonyl)-1-methylhydrazines as anticancer agents.
Sanyal U; De R; Dutta S; Das H; Ghost M
Neoplasma; 1993; 40(4):219-22. PubMed ID: 8272148
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of fluoren-NU as a novel antitumor agent.
Mukherjee A; Dutta S; Chashoo G; Bhagat M; Saxena AK; Sanyal U
Oncol Res; 2009; 17(9):387-96. PubMed ID: 19718945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
